Geert R Kersten, Director and CEO, purchased 25,000 shares of Cel-Sci (CVM) on Jul 06, 2021, for $200,000. After the Form 4 filing with the SEC, Kersten...
Cel-Sci (CVM) said Wednesday that it will hold an investor call on Thursday at the end of its annual shareholder meeting to discuss phase 3 head and neck...
Cel-Sci (CVM) said Monday that its Multikine immunotherapy yielded significant overall survival benefit in patients with advanced and primary squamous cell...
Cel-Sci (CVM) said Friday it closed its offering of 1.4 million common shares priced at $22.62 each for gross proceeds of about $31.7 million. The company...
| Address | 8229 Boone Boulevard Vienna, Virginia 22182 |
| Phone | +1.703.506.9460 |
| Number of Employees | N/A |
| Recent SEC Filing | 01/03/2022 4 |
| CEO, Chief Financial Officer, Treasurer & Director | Geert R. Kersten |
| Secretary & Senior Vice President-Operations | Patricia B. Prichep |
| Chief Scientific Officer | Eyal Talor |
| Vice President-Quality Assurance | William Jones |
| Price Open | $5.80 |
| Previous Close | $5.82 |
| 52 Week Range | $5.63 - 40.91 |
| Market Capitalization | $243.9 M |
| Shares Outstanding | 43.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/15/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.88 |
| Beta vs. S&P 500 | N/A |
| Revenue | $476.6 K |
| Net Profit Margin | N/A |
| Return on Equity | -83.35% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
